|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. COST OF RESISTANCECoast J, Smith RD, Millar MR. 1998. An economic perspective on policy to reduce antimicrobial resistance. Social Science and Medicine46(1):29–38. Phillips M, Phillips-Howard PA. 1996. Economic implications of resistance to antimalarial drugs. Pharmacoeconomics10(3):225–238. Smith RD, Coast J, Millar MR. 1996. Over-the-counter antimicrobials: the hidden costs of resistance. Journal of Antimicrobial Chemotherapy37(5):1031–1032. BACTERIAL RESISTANCEArnadottir T. 2001. Tuberculosis: trends and the twenty-first century. Scandinavian Journal of Infectious Diseases33(8):563–567. Banatvala N, Peremitin GG. 1999. Tuberculosis, Russia, and the Holy Grail. Lancet 353(9157):999–1000. Diwan VK, Thorson A. 1999. Sex, gender, and tuberculosis. Lancet353(9157):1000–1001. Gleissberg V. 1999. The threat of multidrug resistance: is tuberculosis ever untreatable or uncontrollable?Lancet353(9157):998–999. McCormick JB. 1998. Epidemiology of emerging/re-emerging antimicrobial-resistant bacterial pathogens. Current Opinion in Microbiology1(1):125–129. McGee L, McDougal L, Zhou J, Spratt BG, Tenover FC, George R, Hakenbeck R, Hryniewicz W, Lefevre JC, Tomasz A, Klugman KP. 2001. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. Journal of Clinical Microbiology39(7):2565–2571. Available at: http://jcm.asm.org/cgi/content/full/39/7/2565?view=full&pmid=11427569. Pinho MG, Filipe SR, de Lencastre H, Tomasz A. 2001. Complementation of the essential peptidoglycan transpeptidase function of penicillin-binding protein 2 (PBP2) by the drug resistance protein PBP2A in Staphylococcus aureus. Journal of Bacteriology 183(22):6525–6531. Available at: http://jb.asm.org/cgi/content/full/183/22/6525?view=full&pmid=11673420. Somoskovi A, Parsons LM, Salfinger M. 2001. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respiratory Research 2(3):164–168. Available at: http://respiratory-research.com/content/2/3/164. World Health Organization. 2000.Anti-Tuberculosis Drug Resistance in the World. Report No. 2: Prevalence and Trends. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug-Resistance Surveillance. Available at: http://www.who.int/gtb/publications/dritw/index.htm. VIRAL RESISTANCEBlower SM, Porco TC, Darby G. 1998. Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nature Medicine4(6):673–678. Gumina G, Song GY, Chu CK. 2001. Advances in antiviral agents for hepatitis B virus. Antiviral Chemistry and Chemotherapy12 Suppl 1:93–117. Mital D, Pillay D. 2001. The impact of HIV-1 subtype on drug resistance. Journal of HIV Therapy6(3):56–60. Pineo GF, Hull RD. 2001. Dalteparin sodium. Expert Opinion on Pharmacotherapy 2(8):1325–1337.
|
|
|||||||||||||||
